Parkinson’s Disease Market is anticipated to Grow at a CAGR of 5.8% During the Study Period (2020-2034) by DelveInsight
According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately ...
pharmaphorum1d
UCB, Biogen lupus drug scores in phase 3 trial
also partnered with UCB – and felzartamab, an anti-CD38 antibody for IgA nephropathy (IgAN) and other diseases, licensed from Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront ...
Hosted on MSN1mon
UCB drops Parkinson’s treatment after ORCHESTRA trial failed all endpoints
Belgian pharmaceutical company UCB is dropping its development of minzasolmin ... Earlier this year, Annovis Bio announced that its investigational candidate buntanetap tartrate was successful ...
pharmaphorum2d
Roche doubles down on tau for Alzheimer’s, licensing UCB drug for $120m
Roche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a deal with Belgian drugmaker UCB worth up to $2 billion. The Swiss pharma group is paying $ ...